CoChat

Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) are long-acting insulin analogs providing basal insulin supply in multiple daily injection (MDI) therapy of type 1 diabetes (T1D). Both insulins require extensive testing to arrive at the optimal dosing regimen, e.g., timing and amount. Here we aim at a simulation tool for evaluating benefits/risks of different dosing schemes and up-titration rules for both Gla-100 and Gla-300 before clinical testing. METHODS: A new pharmacokinetic (PK) model of both Gla-100 and Gla-300 was incorporated into the FDA-accepted University of Virginia/Padova T1D simulator: Specifically, a joint parameter distribution, built from PK parameter estimates, was used to generate individual PK parametrizations for each in silico subject. A virtual trial comparing Gla-100 vs. Gla-300 was performed and assessed against a clinical study to validate the glargine simulator. RESULTS: Like in vivo, in silico both insulins performed similarly with respect to glucose control: percent time of glucose between [80-140] mg/dL with Gla-100 vs. Gla-300 (primary endpoint) were 41.5 ± 1.1% vs. 39.0 ± 1.2% (P = 0.11) in silico, 31.0 ± 1.6% vs. 31.8 ± 1.5% (P = 0.73) in vivo. CONCLUSIONS: The glargine simulator reproduced the main findings of the clinical trial, proving its validity for testing MDI therapies. SIGNIFICANCE: In silico testing of MDI therapies can help designing clinical trials. Due to the more standardized settings in silico (e.g., standardized meals and strict adherence to titration rule), any potential treatment effect is reaching statistical significance in simulation vs. clinical trial.

Overview

Integrity signals

Registry

Crossref · 10.1109/tbme.2019.2897851

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 22

Metadata

Authors
Visentin, R., Schiavon, M., Giegerich, C., Klabunde, T., Man, C. D., & Cobelli, C.
Affiliations
  • University of Padua (IT)
  • Sanofi (Germany) (DE)
Venue
IEEE Transactions on Biomedical Engineering
Published
2019-10
Volume
66
Issue
10
Pages
2889-2896
ISSN
  • 0018-9294 (ISSN-L)
  • 1558-2531
OpenAlex
W2913964535
Cited by
22
References
25
Citations by year
2025: 3 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 1
FWCI
2.44
Type
journal article
Language
en
Open access
closed
Locations
  • IEEE Transactions on Biomedical Engineering (publishedVersion)
  • PubMed (publishedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
Sanofi
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
long-acting insulin, insulin glargine, type 1 diabetes, UVA/Padova simulator, pharmacokinetic modeling, insulin dosing regimens, glycemic control
MeSH terms
Insulin Glargine, Blood Glucose, Computer Simulation, Diabetes Mellitus, Type 1, Drug Administration Schedule, Humans, Hypoglycemic Agents, Injections, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.